BRINZAGAN™

Brinzolamide Ophthalmic suspension 1P 1% w/v

With Prescription

Group

Glaucoma
Dosage And Administration

When used as monotherapy or adjunctive therapy, one drop of BRINZAGAN™ in the conjunctival sac of the affected eye/s twice daily. Some patients may have better response with one drop, three times a day.
Each mL contains

Brinzolamide (Sterile and micronized) IP 1% w/v
Benzalkonium Chloride Solution (As Preservative) 0.02% w/v
Sterile Aqueous vehicle q.s
Indications and Usage

BRINZAGAN™ is a carbonic anhydrase inhibitor indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma
Active Ingredient

Brinzolamide Ophthalmic suspension 1P 1% w/v
How supplied

BRINZAGAN™ ophthalmic suspension is supplied 5 mL plastic dropper bottles.
SPC

Download Info